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Abstract
Background: Worldwide, 130 million persons are estimated to be infected with HCV. Puebla is the Mexican state
with the highest mortality due to hepatic cirrhosis. Therefore, it is imperative to obtain epidemiological data on
HCV infection in asymptomatic people of this region. The objective of present study was to analyze the prevalence
of antibodies and genotypes of hepatitis C virus (HCV) in blood donors from Puebla, Mexico.
Results: The overall prevalence was 0.84% (515/61553). Distribution by region was: North, 0.86% (54/6270);
Southeast, 1.04% (75/7197); Southwest, 0.93% (36/3852); and Central, 0.79% (350/44234). Ninety-six donors were
enrolled for detection and genotyping of virus, from which 37 (38.5%) were HCV-RNA positive. Detected subtypes
were: 1a (40.5%), 1b (27.0%), mixed 1a/1b (18.9%), undetermined genotype 1 (5.4%), 2a (2.7%), 2b (2.7%), and
mixed 1a/2a (2.7%). All recovered donors with S/CO > 39 were HCV-RNA positive (11/11) and presented elevated
ALT; in donors with S/CO < 39 HCV-RNA, positivity was of 30.4%; and 70% had normal values of ALT. The main risk
factors associated with HCV infection were blood transfusion and surgery.
Conclusions: HCV prevalence of donors in Puebla is similar to other Mexican states. The most prevalent genotype
is 1, of which subtype 1a is the most frequent.
Background
Hepatitis C virus (HCV) infection is an important pub-
lic health concern. Worldwide, 130 million persons
(prevalence of 2-2.2%) are estimated to be infected.
The primary diseases associated with HCV are chronic
hepatitis, cirrhosis, and cellular hepatocarcinoma [1-3].
The actual prevalence of HCV is difficult to assess
because serological tests do not discriminate among
acute, chronic, or resolved infection, and the analyzed
groups in most countries are not representative of the
general population, such as blood donors, drug users,
or individuals with high-risk sexual practices [3,4].
HCV prevalence in Mexico has been analyzed in sev-
eral studies, reporting an average of 1.4% in the open
population and 35% in patients with active hepatitis
[5]. Because HCV is relatively variable, it is currently
grouped in six genotypes and several subtypes. In
Mexico, the prevalence of genotype 1 ranges from 30
to 87.5%, with a predominance of subtypes 1b and 1a.
Genotypes 2 and 3 are less frequent and genotypes 4-6
are unusual in Mexican subjects [6].
In Mexico, cirrhosis has shown an increasing ten-
dency, rising from 12,058 cases in 2005 to 12,996 cases
in 2006. In addition, cirrhosis is the second cause of
death in the 15- to 64-year-old age group, being three
times higher in men than in women. Puebla is the
Mexican state with the highest mortality due to hepa-
tic cirrhosis [7]. Therefore, it is imperative to obtain
epidemiological data on the asymptomatic people,
which may contribute to know, in part, the possible
causes of the high incidence of hepatic diseases in this
region.
The aim of this study was to know the epidemiological
profile of relatively recent infected HCV individuals,
detected as asymptomatic carriers and who were identi-
fied as blood donors in the State of Puebla, Mexico. * Correspondence: gerardo.santos.lopez@gmail.com; julio.reyes@imss.gob.mx
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Seroprevalence of HCV
From 61553 donors analyzed during the study period,
515 (0.84%) were anti-HCV reactive. The overall preva-
lence descended from 0.93% in 2003 to 0.55% in 2006
(Figure 1). The mean prevalence at the more urbanized
central (Angelopolis) region was 0.79% which includes
t h ec i t yo fP u e b l ad el o sA n g e l e s ,t h ec a p i t a lo ft h e
state. In the other regions, either suburban or rural, pre-
valence values ranged from 0.86 to 1.04% (Figure 2). No
significant difference was observed among these regions
(Student’s t-test, p > 0.05).
Low S/CO values (from 1.0 to 4.0) were found in 79%
of reactive donors. The rest of the donors presented S/
CO from 4.1 to 168, which can be considered from
medium to relatively high (Figure 3).
Of 515 reactive donors, 96 accepted to be included in
the subsequent studies ("recovered” donors) and were
interrogated and sampled from June 2005 and Decem-
ber 2006. From these 96 donors, 80% presented low S/
CO values (from 1.0 to 4.0) and the rest presented S/
CO from 4.1 to 168 (Figure 3). These data show that
this sample of 96 donors is representative of the total
population of donors previously analyzed.
HCV-RNA detection
Of the 96 recovered donors, 37 were HCV-RNA positive
(38.5%). The anti-HCV S/CO ratio was related with
positivity to HCV-RNA detection; 100% of donors with
S/CO > 39 were HCV-RNA positive, whereas donors
with lower S/CO values presented progressively redu-
cing percentages of viral RNA detection. In donors with
S/CO from 1 to 2, HCV-RNA was detected only in
13.7% (Figure 4).
Distribution of genotypes
HCV genotypes and subtypes were analyzed in all 37
HCV-RNA positive recovered blood donors. 34 (91.8%)
donors had HCV genotype 1. Of these donors, 2 (5.4%),
15 (40.5%), 10 (27.0%), and 7 (18.9%) had subtypes 1
undetermined, 1a, 1b, and 1a/1b, respectively. One
donor had genotype 2a (2.7%) and another had subtype
2b (2.7%). One donor (2.7%) presented the mixed 1a/2a
genotypes (Table 1).
Risk factors
The main risk factors recognized in recovered donors
were histories of surgery (29.1%) and of blood transfu-
sion (6.2%), with 46 and 50% of HCV-RNA positive,
respectively. Other important risk factors identified were
history of migration (15.6%), dental treatments (14.5%),
multiple sex partners (5.2%), and living with infected
family members (4.16%). In 40.6% of the recovered
donors the risk factor could not be identified.
ALT levels in recovered blood donors
Of 37 HCV-RNA-positive donors, 11 (29.7%) presented
significantly high levels of ALT (68.9 ± 7.1 IU/l). All
donors HCV-RNA-negative presented normal levels of
ALT (30.6 ± 5.6 IU/l), which included individuals with
anti-HCV S/CO from 1 to 16.
Age range of blood donors
The mean age of the 515 reactive donors was 34.5 years,
while that of the 96 recovered donors was 34.6. Among
recovered donors, positive and negative HCV-RNA, there
was no significant difference (34.7 and 38.1 years,
Figure 1 Prevalence rates of anti-HCV blood donors during the studied period in the state of Puebla. Specific anti-HCV antibodies were
detected using the AxSYM HCV 3.0 assay (Abbott Diagnostics). Bars represent the 95% confidence interval.
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hand, the mean age of recovered HCV-RNA-positive
donors was different between the individuals with anti-
HCV S/CO ratios ranging from 1 to 16, and those with S/
CO > 39 (35.5; 95% CI, 31.1-39.8 years and 43.3; 95% CI,
38.4-48.3 years, respectively; Student’st - t e s t ,p = 0.044).
Discussion
Blood donors are a low-risk population, usually present-
ing a lower prevalence than the open population. The
overall prevalence obtained in the present work was
0.84%, this result is in agreement with other studies on
the prevalence among donors in Mexico, which ranges
from 0 to 2%, but most of studies report values > 1%
[6,8]. It is noteworthy that the prevalence values are des-
cending since 2003 (Figure 1), probably due to the
application of a more strict questionnaire to potential
donors, as observed previously [9].
An essential item of the epidemiological profile of this
type of studies are the risk factors that must be consid-
ered during the screening of blood donors in the ques-
tionnaire. In contrast to most studies on Mexican
Figure 2 Distribution of prevalence rates of anti-HCV blood donors by region in the state of Puebla. The Central Region is known as
“Angelopolis”. Bars represent the 95% confidence interval.
Figure 3 Distribution of donors (%) according to anti-HCV (S/CO) values. Comparison of total versus recovered anti-HCV (+) donors.
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history of surgery with no prior history of blood transfu-
sion, which was recognized in 29.1% of the anti-HCV
positive recovered blood donors. Other studies in Puerto
Rico [10] and India [11] have also reported surgery as a
first-order risk factor.
Another important parameter is the antibody quantity,
estimated by the S/CO ratio values in EIA. S/CO ratios
ranged from 1 to 128, and 80% of donors presented low
S/CO values (1-4.1), which represent false positive in
the majority of cases. All donors were asymptomatic at
the moment of sampling, the mean age of blood donors
with S/CO ranging from 1 to 4.1 was 35.5 years,
whereas in the donors with S/CO > 39 it was 43.3 years.
It is noteworthy that the mean age of Mexican infected
patients with clinical symptoms has been calculated in
44 years [12], whereas that of Mexican patients with cir-
rhosis is 52 years [13].
On the other hand, donors with S/CO > 39 presented
significantly higher ALT values than donors with low S/
CO, which has been observed also in other studies
[14-16]; this could be related with a potential hepatic
damage.
The HCV-RNA detection is one of the criteria to start
therapy that depends also on genotype, viral load, and
the degree of liver damage. However, of the 96 recov-
ered donors, only 37 (38.5%) were positive to HCV gen-
ome detection, and more than 60% of the anti-HCV
positive individuals had no viremia. The presence of
specific antibodies against HCV and absence of HCV-
RNA is a common finding and may be related with one
of the following causes: a) the patient has resolved the
infection eliminating the virus, b) the infection is so
recent and there is no sufficient viral load to detect the
virus and the patient should be continuously monitored,
or c) there is a cross reaction with antibodies different
from anti-HCV [17-21].
Conclusions
HCV prevalence among donors in the state of Puebla is
similar to that of other Mexican states. The most
Figure 4 HCV-RNA positivity in recovered blood donors grouped by anti-HCV S/CO ratio values.
Table 1 Genotype and subtype of HCV in the 37 HCV-
RNA-positive recovered donors
Genotype/subtype Frequency Percentage (%)
1* 2 5.4
1a 15 40.5
1b 10 27.0
1a/1b 7 18.9
Genotype 1 34 91.8
2a 1 2.70
2b 1 2.70
Genotype 2 2 5.40
1a/2a 1 2.70
Total 37 100
*Undetermined subtype.
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subtype was 1a (40.5%). The main risk factors recog-
nized in recovered donors were histories of surgery and
of blood transfusion.
Methods
Blood donors
The study population consisted of individuals who
donated blood between January 2003 and December
2006 from the State of Puebla, Mexico, at National
Health Centre “Manuel Avila Camacho”.D u r i n gt h i s
period, 61553 first time donors were analyzed, and were
subjected to routine studies by the Blood Bank, accord-
ing to Mexican Official Standard, NOM-003-SSA2-1993,
including a third generation EIA anti-HCV test. After
that, we invited the positive anti-HCV donors to partici-
pate in this study that included HCV-RNA detection
and quantification of alanine-aminotransferase (ALT)
activity. Individuals who agreed to enter the study were
classified as “recovered” donors. A questionnaire,
requesting information on transfusion, surgical or dialy-
sis history, piercing and tattooing, or sexual practices
and other data, was applied to recovered donors.
Detection of anti-HCV
Screening of blood donors was performed using the
AxSYM HCV 3.0 assay (Abbott Diagnostics, Wiesbaden,
Germany). The AxSYM HCV 3.0 is an indirect micro-
particle enzyme immunoassay (MEIA) that detects
human antibodies against recombinant HCV proteins
core, NS3, NS4, and NS5. The values of antibody detec-
tion are expressed as the ratio between the signals
detected in the sample and the cutoff value (S/CO);
samples with S/CO values ≥ 1.0 were considered reac-
tive [22]. All reactive samples were submitted to a sec-
ond anti-HCV detection test.
HCV RNA detection
RNA in serum samples was extracted using QIAamp
RNA Viral Mini Kit (Qiagen, Valencia, CA). HCV-RNA
was amplified using a nested RT-PCR with the two sets
of primers corresponding to the 5’ UTR, either in the
first or second round, as reported previously [23-25].
Reverse transcription and the first round of PCR (25 μl
reactions) were performed using One-Step RT-PCR with
Platinum Taq (Invitrogen, Carlsbad, CA). Program para-
meters were 55°C for 30 min (RT), 94°C for 2 min, and
40 cycles of 94°C for 30 sec, 56°C for 30 sec, and 72°C
for 30 sec. The second round of PCR (25 μl reactions)
was performed using BioMix (Bioline, London, UK) and
2 μl of first-round PCR product. Thermal cycler condi-
tions were 94°C for 2 min and 40 cycles of 94°C for 30
sec, 60°C for 30 sec, and 72°C for 30 sec. Nested RT-
PCR was performed by duplicate in all samples and
reaction products were analyzed by 1% agarose gel elec-
trophoresis. This home-made RT-PCR has a detection
limit of 50 IU per ml (unpublished results), which is
comparable with commercial test used for qualitative
detection of HCV genome [4].
Genotyping analysis
Viral genotypes were identified by restriction fragment
length polymorphism (RFLP) according to published
protocols [25]. Briefly, the 251-bp amplicon obtained in
nested RT-PCR was digested with enzymes MvaI( F e r -
mentas, Glen Burnie, MD) and HinfI( P r o m e g a ,M a d i -
son, WI) in order to discriminate among viral genotypes
1-6. After that, the 251-bp amplicon was digested with
either BstUI or ScrFI enzymes (New England Biolabs,
Ipswich, MA) to identify viral subtypes. Restriction frag-
ments were analyzed by 15% polyacrylamide gel
electrophoresis.
Alanine-aminotransferase (ALT) determinations
ALT levels were measured with the Advia 1200 Chemistry
System (Siemens healthcare Diagnostics Inc, Tarrytown,
NY) and the normal reference interval were 4-36 IU/l.
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